Skip to main content
. 2009 Jun 18;15(9-10):307–315. doi: 10.2119/molmed.2009.00025

Figure 4.

Figure 4

CD151 gene delivery improves myocardial function. (A) and (B) LVEF% and LVFS% showed myocardial contractile function was improved in the rAAV-CD151 group, but decreased in the rAAV-antiCD151 group 8 wks after vector administration. LVEF, left ventricular ejection fraction; LVFS, left ventricular shortening fraction. (C) and (D) δALWT% and δIVST% showed the regional motion of anterior lateral and interventricular septal wall was improved in the rAAV-CD151 group 8 wks after vector administration. δALWT, anterior lateral wall systolic thickening fraction; δIVST, interventricular septal systolic thickening fraction. (E) and (F) ALWTd and IVSTd showed the thickness of anterior lateral and interventricular septal wall was increased in the rAAV-CD151 group 8 wks after vector administration. ALWTd, anterior lateral wall diastolic thickness; IVSTd, interventricular septal diastolic thickness. Data are presented as mean ± SEM (n = ~4–6 per group). &P < 0.05 versus control group; *P < 0.05 versus control and rAAV-GFP groups; **P < 0.05 versus rAAV-GFP group.